ITL limited’s (ASX:ITD) investee company MyHealthTest Pty Ltd has been awarded an Accelerating Commercialisation grant of up to $1 million from the Commonwealth Department of Industry and Science.
This is for commercialisation of dry blood spot pathology testing and represents 40% of MHT’s approved budget for this project.
The grant will also enable MHT to accelerate the launch of its tests for thyroid and prostate conditions, and help establish advanced laboratory test processing facilities.
MHT allows customers to order a home test kit online that can be received by post or collected from a local pharmacy or GP.
This is then returned to MHT and test results received by the customer and their doctor.
MHT will serve chronic health conditions that require regular blood testing such as diabetes and cardiovascular disease. The Company will shortly launch a test used to diagnose and manage diabetes.
